Rhode Island Biotechnology Company Wins Second National Institutes of Health (NIH) BioDefense Award; EpiVax Wins SBIR Phase I Grant Totaling $993,771 To Develop Smallpox Vaccine 
10/19/2005 5:12:30 PM

PROVIDENCE, R.I.--(BUSINESS WIRE)--Dec. 20, 2004--EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), for developing a genome-derived, epitope-driven smallpox vaccine.